Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026

Tenax Therapeutics, Inc. announced today the topline results of its Phase 3 LEVEL trial, which evaluated TNX-103 (oral levosimendan) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), Group 2 of the World Health Organisation (WHO) pulmonary hypertension classification. The trial did not meet its primary endpoint — improvement in […]

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026 Read Post »

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension, July 16, 2026

Insmed announced on July 16 positive 12-Month data from the ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH, World Health Organization Group 1). The OLE study is a non-placebo-controlled trial and was designed to evaluate the long-term safety, tolerability, and effectiveness of

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension, July 16, 2026 Read Post »

Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): findings from the phase 3 study, The Lancet, July 26, 2026

ADVANCE OUTCOMES is a phase 3, randomised, double-blind trial tested oral ralinepag against placebo in pulmonary arterial hypertension patients, measuring time to first clinical worsening (death, hospitalisation, need for parenteral/inhaled prostacyclin therapy, disease progression, or unsatisfactory clinical response). Patients were enrolled between Jan 24, 2019, and June 20, 2025. Of 1037 patients screened for eligibility,

Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): findings from the phase 3 study, The Lancet, July 26, 2026 Read Post »

U.S. Food and Drug Administration (FDA) grants orphan drug status to IKT-001, an experimental formulation of imatinib to treat pulmonary arterial hypertension, July 23, 2026

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IKT-001, an experimental formulation of imatinib that Inhibikase Therapeutics is developing to treat pulmonary arterial hypertension (PAH). Orphan drug designation is granted to investigational medications aimed at treating rare diseases — conditions affecting fewer than 200,000 people in the U.S. The designation is meant to give

U.S. Food and Drug Administration (FDA) grants orphan drug status to IKT-001, an experimental formulation of imatinib to treat pulmonary arterial hypertension, July 23, 2026 Read Post »

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026

In a single-centre Japanese cohort of 101 patients with haemodynamically severe pulmonary arterial hypertension treated with parenteral prostacyclin (1999–2023), 22 patients (22%) achieved near-normal haemodynamics and were successfully weaned off prostacyclin, all without adverse events, after a mean of 7.7 years of treatment. Those who de-escalated tended to have started prostacyclin earlier in their disease

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026 Read Post »

Phase 2 trial on new investigational treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) completes enrolment, Pulmonary Hypertension News, June 15, 2026

Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) is classified as Group 2 pulmonary hypertension by the World Health Organization (WHO). It is a type of heart failure in which the heart still pumps normally but becomes too stiff to fill properly with blood between heartbeats. This can cause pressure to build

Phase 2 trial on new investigational treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) completes enrolment, Pulmonary Hypertension News, June 15, 2026 Read Post »

Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026

Earlier this month, Liquidia Corporation presented four posters at the US Pulmonary Hypertension Association (PHA)’s International Conference in Dallas, sharing 24‑week ASCENT study data and broader insights on YUTREPIA (treprostinil) inhalation powder in pulmonary hypertension. Beyond clinical outcomes, the company highlighted patient‑reported cough data, the mental health strain on caregivers and the evolving role of

Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026 Read Post »

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026

French researchers retrospectively evaluated the haemodynamic trajectory of 62 patients with pulmonary arterial hypertension (PAH) who sequentially received parenteral prostacyclins and sotatercept as part of the French early access program. They found that both treatments lowered the resistance in the blood vessels of the lungs, making it easier for blood to flow. However, the treatments worked

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026 Read Post »

New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension

New study aims to see how 24 weeks of triple therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and sotatercept, affects pulmonary vascular resistance (PVR) in patients with newly diagnosed pulmonary arterial hypertension. SIRIUS is a 24-week, single-arm, open-label study with up to 42 days of screening and a 28-day safety follow-up.

New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension Read Post »

United Therapeutics presents positive data from ongoing research at the American Thoracic Society’s International Conference, May 15-20, Orlando (US)

United Therapeutics announced positive data from the TETON-1 phase 3 pivotal study of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF), and of the ADVANCE OUTCOMES and ARTISAN studies on pulmonary arterial hypertension at the American Thoracic Society’s International Conference on May 15-20, in Orlando (see also our previous article at this link) The following posters

United Therapeutics presents positive data from ongoing research at the American Thoracic Society’s International Conference, May 15-20, Orlando (US) Read Post »

South Korean biotech GI Innovation files patent for next-generation pulmonary arterial hypertension candidate, The Bio, April 29, 2026

GI Innovation, a South Korean bio-venture company, announced on April 29, 2026, that it has filed a domestic patent application for GI-214 (development code), a pulmonary arterial hypertension (PAH) treatment candidate. GI-214 is positioned as a next-generation candidate targeting the same disease-associated signaling pathway (the activin pathway) as sotatercept, the therapy developed by MSD (Merck

South Korean biotech GI Innovation files patent for next-generation pulmonary arterial hypertension candidate, The Bio, April 29, 2026 Read Post »

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026

Pulnovo Medical, a Shanghai-based company developing therapies for pulmonary hypertension and heart failure, has raised $100 million in a strategic financing round led by Medtronic, which has also entered into a separate commercial agreement with the company exploring future commercialisation opportunities. Pulnovo’s flagship product is the Pulmonary Artery Denervation (PADN) System, a minimally invasive device

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026 Read Post »

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30

One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30 Read Post »

Inhibikase Therapeutics begins pivotal phase 3 trial in pulmonary arterial hypertension, April 7, 2026

Inhibikase Therapeutics has enrolled the first patient in its global pivotal Phase 3 IMPROVE-PAH trial of IKT-001 for pulmonary arterial hypertension. The trial uses a two-part adaptive design: the first part evaluates change in pulmonary vascular resistance in approximately 140 patients over 12 weeks, followed by a second part focusing on six-minute walk distance in

Inhibikase Therapeutics begins pivotal phase 3 trial in pulmonary arterial hypertension, April 7, 2026 Read Post »

AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension with Interstitial Lung Disease (ILD-PH), April 9, 2026

AllRock Bio has dosed the first patients in its Phase 2a ROCSTAR trial, evaluating ROC-101 — a potential first-in-class oral pan-rho-associated protein kinase (ROCK) inhibitor — in patients with pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The open-label, multicenter, exploratory study will evaluate the safety, tolerability, and efficacy of ROC-101 in both

AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension with Interstitial Lung Disease (ILD-PH), April 9, 2026 Read Post »

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026

A Japanese study has confirmed that sotatercept works just as well in Asian patients, even though pulmonary arterial hypertension presents somewhat differently in the Asian population: patients tend to have longer disease duration, more severe baseline profiles, and are more frequently on intensive triple therapy including parenteral prostacyclin. This was a regional Phase 3, open-label

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026 Read Post »

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026

A consensus document featuring 10 statements, the main focus of which was the use of parenteral prostanoids, was developed by eight experts in pulmonary arterial hypertension during in-person and web-based meetings. Forty-six Italian physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement. These consensus statements are intended to support physicians

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026 Read Post »

Results of the PROSERA study for seralutinib in pulmonary arterial hypertension released by Gossamer Bio on February 23, 2026

The PROSERA study for seralutinib in pulmonary arterial hypertension findings were released yesterday and report that it did not meet its primary endpoint in the full population. It appears that unexpected placebo results in some geographical areas may have been responsible for this happening. While this is disappointing news for the patient community the program

Results of the PROSERA study for seralutinib in pulmonary arterial hypertension released by Gossamer Bio on February 23, 2026 Read Post »

Phase 2 PHocus trial of mosliciguat completes enrollment in pulmonary hypertension associated with interstitial lung disease PH-ILD, Pulmonary Hypertension News, February 9, 2026

The February 9 2026 edition of Pulmonary Hypertension News reports that enrollment has been completed in under a year for the PHocus Phase 2 clinical trial testing mosliciguat, a once-daily inhaled therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD)—a condition where current treatment options remain limited and often poorly tolerated. Developed by Pulmovant,

Phase 2 PHocus trial of mosliciguat completes enrollment in pulmonary hypertension associated with interstitial lung disease PH-ILD, Pulmonary Hypertension News, February 9, 2026 Read Post »

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026

A retrospective cohort study using data from 103 healthcare organizations compared 454 pulmonary arterial hypertension patients receiving sotatercept to 963.386 pulmonary arterial hypertension patients not receiving sotatercept. After propensity score matching to balance baseline characteristics, 346 patients per group were analyzed over an average follow-up of approximately 6-8 months. The sotatercept group demonstrated dramatically lower

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026 Read Post »

TRANSLATE »
Scroll to Top